ObjectiveWhile self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) has well-documented benefits. uptake may be improved by addressing client concerns such as fear of self-injury and low self-efficacy. However. current training materials for family planning providers do not address these concerns. https://www.soiebiologique.com/